Due to a production error, an author’s name was incorrectly spelled as “Taka-aki Mastuoka”. The correct spelling is “Taka-aki Matsuoka”. The publisher apologizes for this mistake.
The original version of this article has been updated.
. 2023 Jul 24;14:1257424. doi: 10.3389/fendo.2023.1257424
Erratum: Effect of SARS-CoV-2 BNT162b2 mRNA vaccine on thyroid autoimmunity: a twelve-month follow-up study
Frontiers Production Office1,*
1
Frontiers Media SA, Lausanne, Switzerland
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
✉
*Correspondence: Frontiers Production Office, production.office@frontiersin.org
Received 2023 Jul 12; Accepted 2023 Jul 12; Collection date 2023.
Keywords: SARS-CoV-2, COVID-19, thyroid autoimmunity, BNT162b2 vaccine, thyroid-stimulating hormone receptor antibody, Graves’ disease
Copyright © 2023 Frontiers Production Office
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
PMCID: PMC10406239 PMID: 37554767
This corrects the article "Effect of SARS-CoV-2 BNT162b2 mRNA vaccine on thyroid autoimmunity: A twelve-month follow-up study", 1058007.